This CME-certified Dr prIME Presents activity combines media types to create an informative, engaging educational experience utilizing animation and motion graphics in addition to video and text. The clinical scenario includes decisions for treatment options and patient management, with faculty providing commentary and insight. The case focuses on a patient with newly diagnosed BRAF-positive metastatic melanoma and assessment of the options given the patient and tumor characteristics, then continues into clinical management of the patient. The activity also includes a video that can be utilized as a patient tool to explain BRAF-targeted therapy and the importance of both discussing potential adverse events with the healthcare team and taking the medicine on a regular basis.
- Clinical Case—Treatment Choice
- Adverse Event Management
- Future Directions
- Summary and Patient Video
Jeffrey S. Weber, MD, PhDLaura and Isaac Perlmutter Cancer Center
NYU Langone Medical Center
New York, New York, United States
Sanjiv Agarwala, MDSt Luke’s University Hospital and Temple University
Easton, Pennsylvania, United States
Jeffrey Sosman, MDVanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
This activity is specifically designed for medical oncologists and other healthcare professionals who manage and treat patients with melanoma.
After successful completion of this educational activity, participants should be able to:
- Identify best practices for the treatment of BRAF-mutated melanoma, including strategies to prevent or overcome resistance to single-agent BRAF inhibitor therapy
- Assess recent clinical data supporting emerging targeted agents and combinations of currently approved therapies for unresectable and metastatic melanoma
- Identify the most common adverse events in BRAF inhibitors
This activity is provided by prIME Oncology.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is supported by grants from Genentech and Novartis Oncology.
April 1, 2016
April 1, 2017